ElectroCore Inc (ECOR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$8.99-0.99%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Improve gross profit margins through operational efficiencies: gross margin 86.5% vs 2025-Q3 86.0% (above trip) but down from 2026-Q1 87.3%.
ElectroCore aims for 30% revenue growth in 2026, growing from $6.7M to $9.6M in Q1. Gross profit improved from $7.5M in 2025-Q3 to $8.4M in 2026-Q1. The company is on track with management priorities despite recent losses. Recent earnings beats show potential for recovery.
The company remains loss-making with negative EPS expected through 2027. Recent sharp share price selloff signals investor concern. Revenue growth and margin improvements may stall, risking further losses.
The market is selling off the stock sharply, reflecting concerns about sustained losses and growth risks. There is no clear consensus revenue growth or fair value priced in, leaving uncertainty about future performance.
Breaks if: EPS loss worsens or remains flat beyond 2027
Breaks if: gross profit margin declines below 2025-Q3 levels persistently
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. ECOR is currently loss-making but aims for significant revenue growth and improved profitability over the next few years.
The market seems to reflect a cautious outlook, given ECOR's recent weak financial performance compared to its peers. There is an elevated risk profile, which suggests that investors may be pricing in uncertainty about future earnings and operational execution.
Management is on track to achieve over 30% annual revenue growth in 2026, although the path to positive Adjusted EBITDA by Q3 2027 is mixed. Recent earnings beats indicate some operational strength, but overall financial performance remains weak.
The long-term thesis hinges on the company's ability to maintain revenue growth, manage operational risks, and navigate potential sector-wide challenges. Key factors include the performance of larger healthcare companies and broader economic indicators like job reports.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: annual revenue growth falls below 15% in 2026
In the next 1 to 3 years, ECOR's success will depend on its execution against growth targets and the overall healthcare sector's performance. Not investment advice.